This is therefore a comparing of the profitability, analyst recommendations, risk, dividends, earnings and valuation, institutional ownership in Cellectis S.A. (NASDAQ:CLLS) and Galapagos NV (NASDAQ:GLPG). The two are both Biotechnology companies that compete with one another.

Valuation & Earnings

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cellectis S.A.	25.47M	28.27	82.53M	-2.11	0.00
Galapagos NV	N/A	0.00	N/A	-1.69	0.00

Table 1 showcases the top-line revenue, earnings per share (EPS) and valuation of Cellectis S.A. and Galapagos NV.

Profitability

Table 2 shows the return on equity, net margins and return on assets of the two firms.

	Net Margins	Return on Equity	Return on Assets
Cellectis S.A.	-324.03%	-23%	-18.8%
Galapagos NV	0.00%	0%	0%

Analyst Recommendations

Cellectis S.A. and Galapagos NV Recommendations and Ratings are available in the next table.

	Sell Ratings	Hold Ratings	Buy Ratings	Rating Score
Cellectis S.A.	0	1	0	2.00
Galapagos NV	0	0	6	3.00

Cellectis S.A.’s average price target is $25, while its potential upside is 47.67%. Meanwhile, Galapagos NV’s average price target is $126.5, while its potential upside is 25.76%. Based on the analysts opinion we can conclude, Cellectis S.A. is looking more favorable than Galapagos NV.

Insider and Institutional Ownership

Roughly 29.4% of Cellectis S.A. shares are owned by institutional investors while 19.34% of Galapagos NV are owned by institutional investors.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

	Performance (W)	Performance (M)	Performance (Q)	Performance (HY)	Performance (Y)	Performance (YTD)
Cellectis S.A.	-12.03%	-27.86%	-25.47%	-35.88%	-21.71%	-33.55%
Galapagos NV	1.58%	-6.19%	5.07%	0.46%	20.27%	9.12%

For the past year Cellectis S.A. had bearish trend while Galapagos NV had bullish trend.

Summary

Galapagos NV beats Cellectis S.A. on 7 of the 11 factors.

Cellectis S.A., a gene-editing company, develops and sells immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer in France. The company operates through two segments, Therapeutics and Plants. Its lead product candidate is UCART19, an allogeneic T-cell product candidate for the treatment of CD19 expressing hematologic malignancies, which develop in acute lymphoblastic leukemia (ALL) and CLL. The companyÂ’s products also comprise UCART123 for acute myeloid leukemia indications and blastic plasmacytoid dendritic cell neoplasm; UCARTCS1 for multiple myeloma (MM) indications; UCART22 for ALL; and UCART38 for T-cell ALL and MM. In addition, it focuses on applying its gene-editing technologies to develop new generation plant products in the field of agricultural biotechnology. The company has strategic alliances with Pfizer Inc. to generate CAR T-cells in the field of oncology; Les Laboratoires Servier SAS to develop and commercialize product candidates; The University of Texas MD Anderson Cancer Center to research and develop novel cellular immunotherapies for patients suffering from various liquid tumors; and Cornell University to accelerate the development of a targeted immunotherapy for patients with acute myeloid leukemia. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.

Galapagos NV, a clinical-stage biotechnology company, develops and commercializes novel medicines in Belgium, Croatia, France, and the Netherlands. The companyÂ’s clinical stage programs include filgotinib, which is in Phase III clinical trial for the treatment of rheumatoid arthritis, CrohnÂ’s disease, and ulcerative colitis; GLPG1690, which is in Phase IIa clinical trial for the treatment of idiopathic pulmonary fibrosis; GLPG1972, which is in Phase 1 clinical trial for the treatment of osteoarthritis; and MOR106 that is in atopic dermatitis (AtD) patients in Phase Ib trial. The company has collaboration agreement with Gilead Sciences, Inc. for the development of filgotinib for inflammatory indications; Servier to develop GLPG1972; and AbbVie for discovery, development, and commercialization of potentiator and corrector molecules for the treatment of cystic fibrosis, as well as with MorphoSys for MOR106. It also has a research and development agreement with Pharnext SA to develop a pipeline of synergistic drug combinations for various indications. Galapagos NV was founded in 1999 and is headquartered in Mechelen, Belgium.